Not Signed In -
Pneumonia |
|
|
Clinical Trial: Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus aureus (ATTAIN 1)
This study is currently recruiting patients.
|
Purpose
Study 0015 compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Bacterial Pneumonia | Drug: Telavancin | Phase III |
MedlinePlus related topics: Bacterial Infections; Pneumonia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus
Expected Total Enrollment: 625
Study start: February 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic-care facility
Exclusion Criteria:
- Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy
Location and Contact Information
Texas
Alamo Clinical Research Associates, San Antonio, Texas, 78205, United States; Recruiting
More Information
Record last reviewed: April 2005
Last Updated: April 11, 2005
Record first received: April 11, 2005
ClinicalTrials.gov Identifier: NCT00107952
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-14
Source: ClinicalTrials.gov
Cache Date: April 14, 2005
email this page
print this page
bookmark this page
feedback on this page
